FS, defined by specific CrCl decreases and markers of tubulopathy, is more likely in those who have received or
are currently receiving concomitant lopinavir/ritonavir or who had lower CrCl prior to TDF initiation. Half of those with
protocol-defined FS had CrCl recover to near pre-TDF values during the first year after TDF discontinuation.